Affinity Asset Advisors, LLC

13D and 13G Filings

Issuer % of Class Filed
Schedule 13G · 19 securities · passive
Verrica Pharmaceuticals Inc. 13G/A
VRCA · 92511W207
4.99% 11/13/2026
Event 9/30/2026
NextCure, Inc. 13G/A
NXTC · 65343E207
10.0% 11/13/2026
Event 9/30/2026
Lexeo Therapeutics, Inc. 13G/A
LXEO · 52886X107
9.8% 11/13/2026
Event 9/30/2026
Karyopharm Therapeutics Inc. 13G/A
KPTI · 48576U205
6.5% 11/13/2026
Event 9/30/2026
Helix Acquisition Corp. III 13G/A
HLXC · G4444S107
4.8% 11/13/2026
Event 9/30/2026
Forte Biosciences, Inc. 13G/A
FBRX · 34962G208
0% 11/13/2026
Event 9/30/2026
Equillium, Inc. 13G/A
EQ · 29446K106
4.1% 11/13/2026
Event 9/30/2026
Amanat Acquisition Corp. 13G/A
AMAN · G0375M101
4.8% 11/13/2026
Event 9/30/2026
Jasper Therapeutics, Inc. 13G
JSPR · 471871202
5.6% 11/13/2026
Event 9/30/2026
Research Alliance Corporation III 13G
RACC · G75226103
9.5% 11/13/2026
Event 9/30/2026
Vogenx, Inc. 13G
VOGX · 92859A106
6.2% 11/13/2026
Event 9/30/2026
First Tracks Biotherapeutics, Inc 13G
TRAX · 337185102
5.8% 8/13/2026
Event 6/30/2026
Ovid Therapeutics Inc. 13G/A
OVID · 690469101
7.9% 8/13/2026
Event 6/30/2026
Avalo Therapeutics, Inc. 13G/A
AVTX · 05338F306
5.5% 8/13/2026
Event 6/30/2026
iBio, Inc. 13G/A
IBIO · 451033708
10.0% 8/13/2026
Event 6/30/2026
Ventyx Bioscience, Inc. 13G/A
VTYX · 92332V107
0% 5/14/2026
Event 3/31/2026
Sutro Biopharma, Inc. 13G/A
STRO · 869367201
6.5% 5/14/2026
Event 3/31/2026
Sutro Biopharma, Inc. 13G
STRO · 869367102
Amended under CUSIP 869367201 on 1/29/2026
7.8% 10/23/2025
Event 10/16/2025
Inozyme Pharma, Inc. 13G/A
INZY · 45790W108
2.9% 5/30/2025
Event 5/20/2025

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.